NASDAQ$JAGX

Jaguar Health Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

JAGX Q1 2024 — $2.3M revenue, 31.00 EPS

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Jaguar Health Inc reported Q1 2024 results. Diluted EPS came in at $31.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.3M.
  • Diluted EPS: $31.00.
  • Filed on Form 10-Q (accession 0001558370-24-008050).

Headline financials

Total Revenue

$2.35M

Previous: $1.97M+19.2%
EPS (adj)

-$0.06

Previous: -$2.39+97.5%
Capital Expenditures

$0.00

No prior period
Net Income

-$9.23M

Previous: -$12.2M+24.4%
Operating Income

-$8.22M

Previous: -$9.8M+16.2%
Gross Profit

$1.31M

Previous: $1.63M-19.4%
R&D Expense

$4.31M

No prior period
Stock-Based Comp

$581K

Previous: $480K+21.0%

Revenue & EPS history

Jaguar Health · Revenue · Quarterly

$2.35M

Q1 2024+19.2%vs Q1 2023
Beat estimate in 4 of 13 quarters(31%)
ActualEstimate

Revenue by segment

Jaguar Health · $20.3M total across 2 segments · Q1 2026

  • Human Health
    $19.9M
  • Animal Health
    $345K

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-6.2%

Avg return

Earnings day

-10.0%

Avg return

5 days after

-12.3%

Avg return

30 days after

24%

11 / 45 earnings

Positive

+23.1%

Q3 2023

Best reaction

-36.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.4%-9.6%
Q1 2026-5.0%-13.6%-37.9%
Q3 2025+2.9%-32.0%-33.1%
Q2 2025-17.9%-25.9%-24.3%
Q1 2025+4.8%-22.5%-36.5%
Q4 2024+8.8%-12.6%+144.8%
Q3 2024-4.6%-10.2%-11.1%
Q2 2024-10.8%+5.8%-7.5%
Q1 2024-12.2%-10.7%-78.7%
Q4 2023-17.8%-6.7%+150.0%
Q3 2023+23.1%+31.3%-46.1%
Q2 2023-10.8%-12.6%-44.9%
Q1 2023-31.7%-32.2%-28.6%
Q4 2022-31.0%-44.4%-51.3%
Q3 2022-6.7%-13.3%-25.3%
Q2 2022-8.8%-8.6%-32.6%
Q1 2022-7.1%-1.4%-15.5%
Q4 2021-7.4%+12.8%+42.5%
Q3 2021-16.7%-20.7%-35.1%
Q2 2021-12.8%-15.0%-34.8%
Q1 2021-2.4%+4.7%+37.8%
Q4 2020+13.8%+14.4%-13.2%
Q3 2020-5.9%+2.0%+108.4%
Q2 2020-21.3%-15.3%-36.5%
Q1 2020-1.4%-0.4%-1.4%
Q4 2019-5.9%-6.5%+2.0%
Q3 2019-36.4%-37.9%-45.0%
Q2 2019-23.9%-27.7%-16.4%
Q1 2019+0.6%+4.1%-60.4%
Q4 2018-9.8%-23.9%-38.6%
Q3 2018-4.3%-8.5%-33.2%
Q2 2018-12.4%-19.9%-50.3%
Q1 2018-4.4%-5.7%-26.6%
Q4 2017+4.6%-1.1%-9.3%
Q3 2017-2.4%-5.0%-32.2%
Q2 2017-6.3%-15.4%-19.7%
Q1 2017-1.2%-0.4%-16.4%
Q4 2016-1.1%+10.3%+16.1%
Q3 2016-1.9%-18.8%-15.8%
Q2 2016+3.4%-6.1%-23.1%
Q1 2016+0.6%
Q4 2015+5.6%
Q3 2015+8.0%
Q2 2015-1.7%
Q1 2015-7.4%
Q4 2014
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro